フェンブフェン
4-オキソ-4-(4-ビフェニリル)ブタン酸 · ブフェミド · γ-オキソビフェニル-4-酪酸 · フェンブフェン · γ-オキソ[1,1'-ビフェニル]-4-酪酸 · γ-オキソ-[1,1'-ビフェニル]-4-ブタン酸 · γ-オキソ[1,1'-ビフェニル]-4-ブタン酸 · 4-(4-ビフェニリル)-4-オキソ酪酸
識別子と物理属性
| CAS No. | 36330-85-5 |
|---|---|
| 分子式 | C16H14O3 |
| 平均分子量 | 254.28 g/mol |
| 単同位体質量 | 254.09429431 g/mol |
| SMILES | O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1 |
| InChIKey | ZPAKPRAICRBAOD-UHFFFAOYSA-N |
| PubChem CID | 3335 |
| ChEMBL | CHEMBL277522 |
| ChEBI | CHEBI:31599 |
| EC No. | 252-979-0 |
| DTXSID | DTXSID9023043 |
| 現地名 | フェンブフェン |
化学・物理的性質
| XLogP | 3.2 |
|---|---|
| 極性表面積 | 54.4 |
| 水素結合供与体数 | 1 |
| 水素結合受容体数 | 3 |
| 回転可能結合数 | 5 |
| 重原子数 | 19 |
| 形式電荷 | 0 |
| 複雑度 | 310 |
| 医薬品 | Pharmaceuticals -> Listed in ZINC15 |
| LogP（分配係数） | 2.91 |
| Human Drugs | Pharmaceuticals |
| 融点 | 185-187184-187 °C (lit.) |
| Collision Cross Section | 150.36 Ų [M+H-H2O]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| 沸点 | 357.5°C (rough estimate) |
| 密度 | 1.1565 (rough estimate) |
| 屈折率 | 1.5600 (estimate) |
| 貯蔵条件 | 2-8°C |
| 溶解度 | 水に非常に溶けにくく、アセトン、エタノール (96%)、およびジクロロメタンに溶けにくい。2.212mg/L(25℃) |
| 外観・状態 | Solid |
| pKa（酸解離定数） | pKa 4.3(H2O tundened Iundened) (Uncertain) |
| 色 | White to off-white |
| Merck | 13,3990 |
| 主な用途 | 法医学と毒物学医薬品（低分子化合物）獣医 |
| InChI | 1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19) |
| InChIKey | ZPAKPRAICRBAOD-UHFFFAOYSA-N |
| SMILES | OC(=O)CCC(=O)c1ccc(cc1)-c2ccccc2 |
| EPAの化学物質情報 | [1,1'-Biphenyl]-4-butanoic acid, .gamma.-oxo- (36330-85-5) |
化学的特性
White Solid
安全性と法規制
| GHS 分類 | DangerH301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 42 reports by companies from 2 notifications to the ECHA C&L Inventory. |
|---|---|
| その他の安全情報 | IMAP assessments - [1,1'-Biphenyl]-4-butanoic acid, .gamma.-oxo-: Environment tier I assessment |
| Hazard Classes and Categories | Acute Tox. 3 (100%) |
| 水環境危害等級（WGK） | 3 |
| RTECS 番号 | DV1761000 |
| 輸送番号（UN） | UN 2811 6.1/PG 3 |
| 毒性 | LD50 in various strains of mice, rats (mg/kg): 795-1673, 200-720 orally506-811, 265-575 i.p. (Bolte) |
| 税関コード | 2918300090 |
| 危険文句（R） | 25 |
| 危険表示 | T |
| 安全措置（S） | 28-45 |
| 危険等級 | 6.1Acute Tox. 3 Oral |
| 包装等級 | III |
| 貯蔵分類 | 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects |
用途
用途
有機合成原料、薬理・生理作用研究用。
説明
Fenbufen has been found to be an effective, well-tolerated drug for the treatment of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Fenbufen is prepared by the Friedel-Crafts (aluminum chloride – nitrobenzene) acylation of biphenyl with succinic anhydride. The compound is metabolized in humans first to 4-hydroxy-4-biphenylbutyric acid (tmax 2.5 h) then to 4-biphenyl acetic acid (tmax 7.5 h). Both metabolites are more active than fenbufen itself and circulate for several hours (t1/2 10 h). This slow conversion of fenbufen to active metabolites having relatively long plasma half-lives allows for once a day dosing with this agent.
使用
Cyclo-oxygenase inhibitor; analgesic; anti-inflammatory
一般的な説明
Fenbufen belongs to the class of non-steroidal anti-inflammatory drugs, widely used as an antipyretic and analgesic in medical applications. Its mode of action involves the inhibition of cyclooxygenase enzyme and thereby prevents the synthesis of certain prostaglandins.